# A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Source: https://onco.cc/trials/nct07336446/  
OnCo record `nct07336446` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD9750, Saruparib in prostate cancer, run by AstraZeneca, now recruiting.

## Summary

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs is a phase 1/2 interventional study registered as NCT07336446 by AstraZeneca, with 300 participants planned, started 2026-01-27 and due to reach its primary completion in 2029-01-26. Interventions recorded: AZD9750, AZD5305. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07336446
- Phase: 1/2
- Setting: A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)
- Sponsor: AstraZeneca
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07336446: https://clinicaltrials.gov/study/NCT07336446

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [AZD9750](https://onco.cc/drugs/azd9750/), [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07336446.json